𝗖𝗦𝗟'𝗦 $𝟭.𝟱𝟱𝗕 𝗕𝗘𝗧 𝗢𝗡 𝗔𝗟𝗘𝗡𝗧𝗜𝗦: 𝟯 𝗖𝗟𝗜𝗡𝗜𝗖𝗔𝗟 𝗢𝗨𝗧𝗖𝗢𝗠𝗘𝗦 𝗘𝗫𝗣𝗟𝗔𝗜𝗡𝗘𝗗

An executive due diligence breakdown of the $1.555 Billion global collaboration between CSL Limited and Alentis Therapeutics for Lixudebart (ALE.F02). In this video, we analyze the transaction terms ($355 Million upfront + $1.2 Billion in milestones with a 55/45 profit split), the novel exposed Claudin-1 (CLDN1) anti-fibrotic mechanism of action, and Alentis' 3 key clinical outcomes across rare renal and liver indications. EXECUTIVE SUMMARY & DEAL STRUCTURE Parties: CSL Limited and Alentis Therapeutics Lead Asset: Lixudebart (formerly ALE.F02), humanized IgG1 monoclonal antibody Target: Non-junctional / exposed Claudin-1 (CLDN1) Upfront Consideration: $355 Million cash (22.8% of headline value) Milestone Structure: Up to $1.2 Billion commercial milestones (77.2% contingent) Profit Split: 55% CSL / 45% Alentis Therapeutics Development Funding: CSL fully funds Phase 2/3 trials across lead indications ALENTIS' 3 POTENTIAL CLINICAL OUTCOMES AAV-RPGN (ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis): The lead validation indication targeting renal preservation and eGFR recovery alongside standard immunosuppression. FSGS (Focal Segmental Glomerulosclerosis): Addressing a major chronic rare kidney disease market (over 30,000 US addressable patients) through anti-fibrotic disease modification. PSC (Primary Sclerosing Cholangitis): The asymmetric liver fibrosis opportunity with zero FDA-approved disease-modifying therapies, offering high upside in an uncontested space. CHAPTER TIMESTAMPS 00:00 - Executive Overview: The CSL-Alentis $1.555B Strategic Deal 01:15 - Transaction Economics: $355M Upfront & 55/45 Profit Split 02:40 - Mechanism of Action: Targeting Exposed Claudin-1 (CLDN1) 04:05 - Clinical Outcome 1: AAV-RPGN (Rare Renal Lead Indication) 05:45 - Clinical Outcome 2: FSGS (Kidney Preservation & Market Expansion) 07:20 - Clinical Outcome 3: PSC (Unlocking Liver Fibrosis White Space) 08:50 - Financial Valuation: Bear, Base, and Bull Scenario Models 10:25 - Portfolio Fit: Strategic Impact on CSL Vifor's Franchise 12:00 - Final Due Diligence Verdict & Key Catalysts KEY TAKEAWAYS FOR INVESTORS & BIOPHARM Platform Validation: Alentis monetizes its lead anti-fibrotic asset while preserving its broader CLDN1 platform, ADCs, and oncology pipeline. Paradigm Shift: CSL moves from upstream complement/immune suppression toward downstream organ preservation and tissue repair. Risk-Sharing Architecture: Back-loaded commercial milestones protect CSL's capital while funding Phase 3 multi-indication development. DISCLAIMER This video is for educational and strategic informational purposes only and does not constitute financial, investment, or clinical advice. #Biotech #PharmaDeals #CSL #Alentis #Nephrology #Fibrosis #DrugDevelopment #Biopharma #HealthcareInvesting